• PN: B113336


45x Ab-conjugated beads (S5P5-human sEPOR Ab-bead). PN: B113336A. One vial containing 100 µL of anti-human sEPOR conjugated to AimPlex Bead S5P5.

25x Biotin-detection (human sEPOR Biotin-dAb). PN: B113336B. One vial containing 100 µL of biotinylated anti-human sEPOR.

Lyophilized Standard Mix-Human Group 9 Panel B, 9-Plex. PN: HG9009B. One vial containing lyophilized recombinant human sCEACAM-1, sALCAM, sSLAMF4, sHVEM, sB7-DC, sB7-H1, sEpCAM, sBLAME and sEPOR.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human Human EpoR/Erythropoietin Receptor. Can be multiplexed with other analytes in Human Group 9.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 20 pg/mL

Quantitation range:

LLOQ: < 450 pg/mL

ULOQ: > 10,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 9: Negligible

Sample volume: 15 µL/test


The erythropoietin receptor (EpoR) is a peptide and a member of the cytokine receptor family.  At present, the most well-established function of EpoR is to rescue sufficient numbers of erythroid progenitors from cell death.  Additionally, EpoR has been implicated in suppressing expression of death receptors Fas, Trail and TNFa that negatively affect erythropoiesis. Defects in the erythropoietin receptor may produce erythroleukemia and familial erythrocytosis. Overproduction of red blood cells increases a chance of adverse cardiovascular event, such as thrombosis and stroke. Rarely, seemingly beneficial mutations in the EpoR may arise, where increased red blood cell number allows for improved oxygen delivery in athletic endurance events with no apparent adverse effects upon the athlete's health (as for example in the Finish athlete Eero Mäntyranta). Erythropoietin is necessary to maintain endothelial cells and to promote tumor angiogenesis, hence the dysregulation of EpoR may affect the growth of certain tumors. EpoR signaling prevents neuronal death and ischemic injury.


1.       Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. (February 1999). "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation.". Science 283 (5404): 987–90. doi:10.1126/science.283.5404.987. PMID 9974392.

2.       Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF (May 1993). "Structure, function, and activation of the erythropoietin receptor". Blood 81 (9): 2223–36. PMID 8481505.

3.       Wilson IA, Jolliffe LK (December 1999). "The structure, organization, activation and plasticity of the erythropoietin receptor". Curr. Opin. Struct. Biol. 9 (6): 696–704. doi:10.1016/S0959-440X(99)00032-9. PMID 10607675.

4.       Farrell F, Lee A (2004). "The erythropoietin receptor and its expression in tumor cells and other tissues". Oncologist. 9 Suppl 5: 18–30. doi:10.1634/theoncologist.9-90005-18. PMID 15591419.